Sutro Biopharma financials
$16.10+0.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M | $42.7M | $42.7M | $38.4M |
| Gross profit | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M | $42.7M | $42.7M | $38.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$158.4M | -$238.5M | -$89.3M | -$128.9M | -$98.5M | -$71.1M | -$55.5M | -$37.2M |
| Net income | -$191.1M | -$227.5M | -$106.8M | -$119.2M | -$105.5M | -$32.1M | -$55.7M | -$35.3M |
| Net margin | −186.5% | −366.6% | −69.5% | −175.9% | −170.6% | −75.2% | −130.4% | −91.9% |
| Diluted EPS | $-22.49 | $-29.40 | $-17.80 | $-23.50 | $-2.29 | $-0.99 | $-2.43 | $-61.30 |
| EBITDA | -$97.6M | -$231.2M | -$82.5M | -$123.3M | -$93.7M | -$66.8M | -$50.7M | -$32.7M |
| Operating cash flow | -$177.2M | -$191.5M | -$111.6M | $3.5M | -$81.7M | -$67.8M | -$65.0M | $12.7M |
| Free cash flow | -$178.9M | -$194.6M | -$115.9M | -$4.3M | -$97.0M | -$74.9M | -$68.5M | $11.1M |
| Diluted shares | 8.5M | 7.7M | 6.0M | 5.1M | 46.1M | 32.6M | 23.0M | 0.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $58.1M | $190.3M | $69.3M | $47.3M | $30.4M | $206.2M |
| Short-term investments | $83.3M | $126.6M | $306.4M | $287.1M | $167.5M | $162.0M |
| Total debt | $0.00 | $0.00 | $4.1M | $16.3M | $25.1M | $24.5M |
| Total assets | $173.8M | $387.2M | $470.7M | $406.9M | $341.4M | $394.1M |
| Total liabilities | $306.3M | $342.6M | $321.1M | $189.9M | $88.8M | $62.1M |
| Shareholders' equity | -$132.5M | $44.6M | $149.6M | $217.0M | $252.6M | $332.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology